

- Helweg-Larsen S, Sorensen PS, Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. *Int J Radiat Oncol Biol Phys* 2000;46:1163–1169.
- Bilsky MH, Lis E, Raizer J, et al. The diagnosis and treatment of metastatic spinal tumor. *Oncologist* 1999;4:459–469.
- Klimo P Jr, Thompson CJ, Kestle JR, et al. A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. *Neuro Oncol* 2005;7:64–76.
- Nelson KA, Walsh D, Abdullah O, et al. Common complications of advanced cancer. *Semin Oncol* 2000;27:34–44.
- Quinn JA, DeAngelis LM. Neurologic emergencies in the cancer patient. *Semin Oncol* 2000;27:311–321.
- Kovner F, Spigel S, Rider I, et al. Radiation therapy of metastatic spinal cord compression. Multidisciplinary team diagnosis and treatment. *J Neurooncol* 1999;42:85–92.
- Loblaw DA, Laperriere NJ, Mackillop WJ. A population-based study of malignant spinal cord compression in Ontario. *Clin Oncol (R Coll Radiol)* 2003;15:211–217.
- Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression. *Acta Neurochir (Wien)* 1990;107:37–43.
- Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. *J Clin Oncol* 1998;16:1613–1624.
- Prasad D, Schiff D. Malignant spinal-cord compression. *Lancet Oncol* 2005;6:15–24.
- Posner JB. Back pain and epidural spinal cord compression. *Med Clin North Am* 1987;71:185–205.
- Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. *Int J Radiat Oncol Biol Phys* 1995;32:959–967.
- Barron KD, Hirano A, Araki S, et al. Experiences with metastatic neoplasms involving the spinal cord. *Neurology* 1959;9:91–106.
- Helweg-Larsen S. Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. *Acta Neurol Scand* 1996;94:269–275.
- Schiff D, O'Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy. *Neurology* 1997;49:452–456.
- McDonald AC, Nicoll JA, Rampling RP. Non-Hodgkin's lymphoma presenting with spinal cord compression; a clinicopathological review of 25 cases. *Eur J Cancer* 2000;36:207–213.
- Bach F, Agerlin N, Sorensen JB, et al. Metastatic spinal cord compression secondary to lung cancer. *J Clin Oncol* 1992;10:1781–1787.
- Levack P, Graham J, Collie D, et al. Don't wait for a sensory level—listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression. *Clin Oncol (R Coll Radiol)* 2002;14:472–480.
- Greenberg HS, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. *Ann Neurol* 1980;8:361–366.
- Schiff D, O'Neill BP, Wang CH, et al. Neuroimaging and treatment implications of patients with multiple epidural spinal metastases. *Cancer* 1998;83:1593–1601.
- Bouffet E, Marec-Berard P, Thiesse P, et al. Spinal cord compression by secondary epi- and intradural metastases in childhood. *Childs Nerv Syst* 1997;13:383–387.
- Antunes NL. Acute neurologic complications in children with systemic cancer. *J Child Neurol* 2000;15:705–716.
- Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma. *Cancer* 1950;3:74–85.
- Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. *Cancer Treat Rev* 2001;27:165–176.
- Coleman RE. Skeletal complications of malignancy. *Cancer* 1997;80:1588–1594.
- Healey JH, Brown HK. Complications of bone metastases: surgical management. *Cancer* 2000;88:2940–2951.
- Posner JB. Neurological complications of systemic cancer. *Med Clin North Am* 1971;55:625–646.
- Mullins GM, Flynn JP, el-Mahdi AM, et al. Malignant lymphoma of the spinal epidural space. *Ann Int Med* 1971;74:416–423.
- Schiff D, O'Neill BP. Intramedullary spinal cord metastases. *Neurology* 1996;47:906–912.
- Hardy JR, Huddart R. Spinal cord compression—what are the treatment standards? *Clin Oncol (R Coll Radiol)* 2002;14:132–134.
- Sorensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. *Eur J Cancer* 1994;30A:22–27.
- Delattre JY, Arbit E, Rosenblum MK, et al. High dose versus low dose dexamethasone in experimental epidural spinal cord compression. *Neurosurgery* 1988;22:1005–1007.
- Heimdal K, Hirschberg H, Slettebo H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. *J Neurooncol* 1992;12:141–144.
- Klimo P Jr, Kestle JR, Schmidt MH. Treatment of metastatic spinal epidural disease: a review of the literature. *Neurosurg Focus* 2003;15:E1.
- Rades D, Fehlauer F, Schulte R, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. *J Clin Oncol* 2006;24:3388–3393.
- Rades D, Lange M, Veninga T, et al. Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. *Int J Radiat Oncol Biol Phys* 2011;79:524–530.
- Rades D, Freundt K, Meyners T, et al. Dose escalation for metastatic spinal cord compression in patients with relatively radioresistant tumors. *Int J Radiat Oncol Biol Phys* 2011;80:1492–1497.
- Yamada Y, Lovelock DM, Yenice KM, et al. Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report. *Int J Radiat Oncol Biol Phys* 2005;62:53–61.
- Gerszten PC, Burton SA, Ozhasoglu C, et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. *Spine (Phila Pa 1976)* 2007;32:193–199.
- Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. *Int J Radiat Oncol Biol Phys* 2008;71:484–490.
- Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? *Spine (Phila Pa 1976)* 2009;34:S78–S92.
- Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. *Lancet Oncol* 2012;13:395–402.
- Young RF, Post EM, King GA. Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. *J Neurosurg* 1980;53:741–748.
- Rades D, Huttenlocher S, Dunst J, et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. *J Clin Oncol* 2010;28:3597–3604.
- Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. *Lancet* 2005;366:643–648.
- Sundaresan N, Sachdev VP, Holland JF, et al. Surgical treatment of spinal cord compression from epidural metastasis. *J Clin Oncol* 1995;13:2330–2335.
- Wong ET, Portlock CS, O'Brien JP, et al. Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma. *Neurology* 1996;46:1543–1547.
- Grommes C, Bosl GJ, DeAngelis LM. Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. *Cancer* 2011;117:1911–1916.
- Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *J Clin Oncol* 2013;31:2347–2357.
- Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. *Lancet Oncol* 2011;12:743–752.
- Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. *J Clin Oncol* 2005;23:3314–3321.
- Rosen LS, Gordon D, Tchekmedyan S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. *J Clin Oncol* 2003;21:3150–3157.
- Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol* 2011;29:1125–1132.
- Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 2011;377:813–822.
- Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010;28:5132–5139.
- Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. *Lancet Oncol* 2012;13:1210–1217.
- Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients. *Cancer* 1991;67:1311–1317.
- Rades D, Blach M, Nerretter V, et al. Metastatic spinal cord compression. Influence of time between onset of motoric deficits and start of irradiation on therapeutic effect. *Strahlenther Onkol* 1999;175:378–381.

1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. *N Engl J Med* 2011;364:1844–1854.
2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. *Br J Haematol* 2004;127:3–11.
3. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. *Am J Med* 1980;68:486–491.
4. Altman A. Acute tumor lysis syndrome. *Semin Oncol* 2001;28:3–8.
5. Sallan S. Management of acute tumor lysis syndrome. *Semin Oncol* 2001;28:9–12.
6. Fleming DR, Doukas MA. Acute tumor lysis syndrome in hematologic malignancies. *Leuk Lymphoma* 1992;8:315–318.
7. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. *Am J Med* 1993;94:133–139.
8. Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. *Support Care Cancer* 2003;11:249–257.
9. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors—a case report and review of the literature. *Cancer Chemother Pharmacol* 2003;51:187–192.
10. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. *Blood* 2007;109:399–404.
11. Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. *Br J Haematol* 2010;149:578–586.
12. Yeldandi AV, Yeldandi V, Kumar S, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. *Gene* 1991;109:281–284.
13. Zimm S, Collins JM, Oneill D, et al. Inhibition of first-past metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. *Clin Pharmacol Ther* 1983;34:810–817.
14. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. *J Clin Oncol* 2010;28:4207–4213.
15. Navolanic PM, Pui CH, Larson RA, et al. Elitec-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. *Leukemia* 2003;17:499–514.
16. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. *Blood* 2001;97:2998–3003.
17. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. *Leuk Res* 2005;29:463–465.
18. Hutcherson DA, Gammon DC, Bhatt MS, et al. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. *Pharmacotherapy* 2006;26:242–247.
19. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. *Bone Marrow Transplant* 2006;37:997–1001.
20. Trifilio SM, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. *Bone Marrow Transplant* 2011;46:800–805.
21. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatremia in medical cancer patients: epidemiology, aetiology and differential diagnosis. *Support Care Cancer* 2000;8:192–197.
22. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med* 2007;356:2064–2072.
23. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med* 2013;126:S1–S42.
24. Sachs J, Fredman B. The hyponatremia of multiple myeloma is true and not pseudohyponatremia. *Med Hypotheses* 2006;67:839–840.
25. Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. *Am J Respir Crit Care Med* 1997;156:1669–1678.
26. Chute JP, Taylor E, Williams J, et al. A metabolic study of patients with lung cancer and hyponatremia of malignancy. *Clin Cancer Res* 2006;12:888–896.
27. Peri A. Clinical review: the use of vaptans in clinical endocrinology. *J Clin Endocrinol Metab* 2013;98:1321–1332.
28. Gargani L, Schmidt PH, Gheorghiane M. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion. *Expert Rev Cardiovasc Ther* 2011;9:1505–1513.
29. Sillos EM, Shenep JL, Burghen GA, et al. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. *Cancer* 2001;92:2237–2246.
30. Tiefenthaler M, Amberger A, Bacher N, et al. Increased lactate production follows loss of mitochondrial membrane potential during apoptosis of human leukaemia cells. *Br J Haematol* 2001;114:574–580.
31. van der Beek A, de Meijer PH, Meinders AE. Lactic acidosis: pathophysiology, diagnosis and treatment. *Neth J Med* 2001;58:128–136.
32. Esbrit P. Hypercalcemia of malignancy—new insights into an old syndrome. *Clin Lab* 2001;47:67–71.
33. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. *N Engl J Med* 2005;352:373–379.
34. Benford HL, Frith JC, Auriola S, et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. *Mol Pharmacol* 1999;56:131–140.
35. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. *J Bone Miner Res* 1998;13:581–589.
36. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. *Br J Cancer* 1995;72:1289–1293.
37. Walker P, Watanabe S, Lawlor P, et al. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. *Ann Oncol* 1997;8:915–916.
38. Vinholes J, Guo CY, Purohit OP, et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. *J Clin Oncol* 1997;15:131–138.
39. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. *Cochrane Database Syst Rev* 2012;5:CD003188.
40. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. *J Clin Oncol* 2001;19:558–567.
41. Walls J, Ratcliffe WA, Howell A, et al. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. *Br J Cancer* 1994;70:169–172.
42. Warrell RP Jr. Gallium nitrate for the treatment of bone metastases. *Cancer* 1997;80:1680–1685.
43. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. *Cancer* 2001;92:460–470.
44. Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. *Cancer* 2013;119:832–838.
45. Fizazi K, Carducci MA, Smith MR, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 2011;377:813–822.
46. Hu MI, Glezerman I, Lebouilleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. *J Natl Cancer Inst* 2013;105:1417–1420.
47. Mungall S, Mathieson P. Hemolytic uremic syndrome in metastatic adenocarcinoma of the prostate. *Am J Kidney Dis* 2002;40:1334–1336.
48. Gordon LI, Kwaan HC. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Semin Hematol* 1997;34:140–147.
49. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. *Cancer* 1986;58:1428–1436.
50. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic uremic syndrome. *Am J Kidney Dis* 2002;40:E16.
51. Verburgh CA, Vermeij CG, Zijlman JM, et al. Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature. *Nephrol Dial Transplant* 1996;11:1332–1337.
52. Martinez MT, Bucher Ch, Stussi G, et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. *Bone Marrow Transplant* 2005;36:993–1000.
53. Snyder HW Jr, Mittelman A, Oral A, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. *Cancer* 1993;71:1882–1892.
54. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. *Ther Apher* 2002;6:320–328.
55. Kaplan AA. Therapeutic apheresis for cancer related hemolytic uremic syndrome. *Ther Apher* 2000;4:201–206.
56. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. *Medicine (Baltimore)* 2012;91:195–205.